Evaluate Safety, Tolerability and PK of HLX55 in Patients With Advanced Solid Tumors With Different cMET Status
- First Posted Date
- 2019-11-19
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- Henlix, Inc
- Target Recruit Count
- 98
- Registration Number
- NCT04169178
- Locations
- π¨π³
Taipei Minicipal Wangfang Hospital, Taipei, Taiwan
π¨π³National Cheng Kung University Hospital, Tainan, Taiwan
π¨π³Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare, Taipei county, Taiwan
Evaluate the Efficacy and Safety of HLX10 in Chronic Hepatitis B Patients
Phase 2
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: Recombinant anti-programmed death-1 (PD-1) humanized monoclonal antibodyDrug: Nucleoside/nucleotide analogues
- First Posted Date
- 2019-10-21
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- Henlix, Inc
- Target Recruit Count
- 44
- Registration Number
- NCT04133259
- Locations
- π¨π³
National Taiwan University Hospita, Taipei, Taiwan
π¨π³Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
π¨π³China Medical University Hospital, Taichung, Taiwan
A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors
Phase 1
Terminated
- Conditions
- Solid Tumor, Adult
- Interventions
- Drug: HLX06
- First Posted Date
- 2018-04-11
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Henlix, Inc
- Target Recruit Count
- 5
- Registration Number
- NCT03494231
- Locations
- π¨π³
Taipei Medical University-Shuang Ho Hospital, New Taipei City, Taiwan
Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors
- First Posted Date
- 2018-03-19
- Last Posted Date
- 2020-06-01
- Lead Sponsor
- Henlix, Inc
- Target Recruit Count
- 30
- Registration Number
- NCT03468751
- Locations
- π¨π³
Taipei Municipal Wanfang Hospital, Taipei City, Taiwan
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers
Phase 1
Completed
- Conditions
- Solid Tumour
- Interventions
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Henlix, Inc
- Target Recruit Count
- 19
- Registration Number
- NCT02648490
- Locations
- πΊπΈ
Henlix, Inc., Fremont, California, United States
π¨π³Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan
Β© Copyright 2025. All Rights Reserved by MedPath